Pathogenetic Mechanisms of Septic Shock

New England Journal of Medicine

Volumn 328, Issue 20, 1993, Pages 1471-1477

  Epstein, Franklin H ^a   Parrillo, Joseph E ^b  

^a Rush Presbyterian St Luke's Medical Center ^*

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; ANTIBIOTIC AGENT; LACTIC ACID; LIPID A; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

ANIMAL; CARDIOVASCULAR SYSTEM; HEART MUSCLE ISCHEMIA; HUMAN; MULTIPLE ORGAN FAILURE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SEPTIC SHOCK; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CELL METABOLISM; HEMODYNAMICS; HYPOTENSION; HYPOVOLEMIA; INTENSIVE CARE; MORTALITY; MYOCARDIAL DISEASE; NONHUMAN; OXYGEN CONSUMPTION; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; SEPSIS;

ANIMAL; CARDIOVASCULAR SYSTEM; ENDOTOXINS; HUMAN; MULTIPLE ORGAN FAILURE; MYOCARDIAL ISCHEMIA; SHOCK, SEPTIC;

EID: 0027920980     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199305203282008     Document Type: Review

References (53)

1. Parrillo JE, moderator Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990; 113:227-242
2. Increase in National Hospital Discharge Survey rates for septicemia – United States, 1979-1987. MMWR Morb Mortal Wkly Rep 1990; 39:31-34
3. Bone RC Sepsis, the sepsis syndrome, multi-organ failure: a plea for comparable definitions. Ann Intern Med 1991; 114:332-333
4. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
5. Parker MM, Shelhamer JH, Natanson C, Alling DW, Parrillo JE Serial cardiovascular variables in survivors and nonsurvivors in human septic shock: heart rate as an early predictor of prognosis. Crit Care Med 1987; 15:923-929
6. Parker MM, Shelhamer JH, Bacharach SL, Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984; 100:483-490
7. Parker MM, McCarthy KE, Ognibene FP, Parrillo JE Right ventricular dysfunction and dilatation, similar to left ventricular changes, characterize the cardiac depression of septic shock in humans. Chest 1990; 97:126-131
8. Ognibene FP, Parker MM, Natanson C, Shelhamer JH, Parrillo JE Depressed left ventricular performance: response to volume infusion in patients with sepsis and septic shock. Chest 1988; 93:903-910
9. Parker MM, Ognibene FP, Parrillo JE Reversible depression of myocardial function in septic shock (SS) confirmed by a load-independent measure of ventricular performance. Clin Res 1990; 38:340A-340A abstract.
10. Parker MM, Suffredini AF, Natanson C, Ognibene FP, Shelhamer JH, Parrillo JE Responses of left ventricular function in survivors and nonsurvivors of septic shock. J Crit Care 1989; 4:19-25
11. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parrillo JE Endotoxemia in human septic shock. Chest 1991; 99:169-175
12. Suffredini AF, Fromm RE, Parker MM, The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989; 321:280-287
13. Natanson C, Fink MP, Ballantyne HK, MacVittie TJ, Conklin JJ, Parrillo JE Gram-negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in a canine model that simulates human septic shock. J Clin Invest 1986; 78:259-270
14. Natanson C, Danner RL, Elin RJ, Role of endotoxemia in cardiovascular dysfunction and mortality: Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock. J Clin Invest 1989; 83:243-251
15. Natanson C, Eichenholz PW, Danner RL, Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 1989; 169:823-832
16. Beutler B, Milsark IW, Cerami AC Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229:869-871
17. Cunnion RE, Schaer GL, Parker MM, Natanson C, Parrillo JE The coronary circulation in human septic shock. Circulation 1986; 73:637-644
18. Lefer AM, Martin J Origin of myocardial depressant factor in shock. Am J Physiol 1970; 218:1423-1427
19. Carli A, Auclair MC, Benassayag C, Nunez E Evidence for an early lipid soluble cardiodepressant factor in rat serum after a sublethal dose of endotoxin. Circ Shock 1981; 8:301-312
20. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W A circulating myocardial depressant substance in humans with septic shock: septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest 1985; 76:1539-1553
21. Reilly JM, Cunnion RE, Burch-Whitman C, Parker MM, Shelhamer JH, Parrillo JE A circulating myocardial depressant substance is associated with cardiac dysfunction and peripheral hypoperfusion (lactic acidemia) in patients with septic shock. Chest 1989; 95:1072-1080
22. Kumar A, Dimou C, Hollenberg SM, Tumor necrosis factor produces a concentration-dependent depression of myocardial cell contraction in vitro. Clin Res 1991; 39:321A-321A abstract.
23. Danner RL, Suffredini AF, Natanson C, Parrillo JE. Microbial toxins: role in the pathogenesis of septic shock and multiple organ failure. In: Bihari DJ, Cerra FB, eds. Multiple organ failure. Fullerton, Calif.: Society of Critical Care Medicine, 1989:151-91.
24. Springer TA Adhesion receptors of the immune system. Nature 1990; 346:425-434
25. Ognibene FP, Parker MM, Burch-Whitman C, Neutrophil aggregation activity and septic shock in humans: neutrophil aggregation by a C5a-like material occurs more frequently than complement component depletion and correlates with depression of systemic vascular resistance. J Crit Care 1988; 3:103-111
26. Sakuma I, Stuehr DJ, Gross SS, Nathan C, Levi R Identification of arginine as a precursor of endothelium-derived relaxing factor. Proc Natl Acad Sci U S A 1988; 85:8664-8667
27. G-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci U S A 1990; 87:3629-3632
28. Hollenberg SM, Cunnion RE, Parrillo JE The effect of tumor necrosis factor on vascular smooth muscle: in vitro studies using rat aortic rings. Chest 1991; 100:1133-1137
29. Dantzker DR, Foresman B, Gutierrez G Oxygen supply and utilization relationships: a reevaluation. Am Rev Respir Dis 1991; 143:675-679
30. Gilbert EM, Haupt MT, Mandanas RY, Huaringa AJ, Carlson RW The effect of fluid loading, blood transfusion, and catecholamine infusion on oxygen delivery and consumption in patients with sepsis. Am Rev Respir Dis 1986; 134:873-878
31. 18F]fluoromisonidazole. Am J Physiol 1991; 261: R965-R972
32. Hotchkiss RS, Karl IE Reevaluation of the role of cellular hypoxia and bioenergetic failure in sepsis. JAMA 1992; 267:1503-1510
33. Solomon MA, Alexander HR, Balaban RS, Myocardial cytosolic phosphorylation potential in a canine sepsis model. Clin Res 1991; 39:164A-164A abstract.
34. Dantzker D Oxygen delivery and utilization in sepsis. Crit Care Clin 1989; 5:81-98
35. Vincent JL, Dufaye P, Berre J, Leeman M, Degaute JP, Kahn RJ Serial lactate determinations during circulatory shock. Crit Care Med 1983; 11:449-451
36. Shoemaker WC, Appel PL, Kram HB Tissue oxygen debt as a determinant of lethal and nonlethal postoperative organ failure. Crit Care Med 1988; 16:1117-1120
37. Tuchschmidt J, Fried J, Astiz M, Rackow E Elevation of cardiac output and oxygen delivery improves outcomes in septic shock. Chest 1992; 102:216-220
38. Suffredini AF, Shelhamer JH, Neumann RD, Brenner M, Baltaro RJ, Parrillo JE Pulmonary and oxygen transport effects of intravenously administered endotoxin in normal humans. Am Rev Respir Dis 1992; 145:1398-1403
39. Suffredini AF, Harpel PC, Parrillo JE Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320:1165-1172
40. Parrillo JE Management of septic shock: present and future. Ann Intern Med 1991; 115:491-493
41. Kreger BE, Craven DE, McCabe WR Gram-negative bacteremia. IV. Reevaluation of clinical features and treatment in 612 patients. Am J Med 1980; 68:344-355
42. Li TCM, Phillips MC, Shaw L, Cook EF, Natanson C, Goldman L On-site physician staffing in a community hospital intensive care unit: impact on test and procedure use and on patient outcome. JAMA 1984; 252:2023-2027
43. Reynolds HN, Haupt MT, Thill-Baharozian MC, Carlson RW Impact of critical care physician staffing on patients with septic shock in a university hospital medical intensive care unit. JAMA 1988; 260:3446-3450
44. Natanson C, Danner RL, Reilly JM, Antibiotics versus cardiovascular support in a canine model of human septic shock. Am J Physiol 1990; 259: H1440-H1447
45. Bone RC, Fisher CJ Jr, Clemmer TP, A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317:653-658
46. Ziegler EJ, McCutchan JA, Fierer J, Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982; 307:1225-1230
47. Greenman RL, Schein RMH, Martin MA, A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991; 266:1097-1102
48. Ziegler EJ, Fisher CJ Jr, Sprung CL, Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1991; 324:429-436
49. Danner RL, Joiner KA, Parrillo JE Inhibition of endotoxin-induced priming of human neutrophils by lipid X and 3-Aza-lipid X. J Clin Invest 1987; 80:605-612
50. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348:550-552
51. Natanson C, Hoffman WD, Danner RL, A controlled trial of plasmapheresis fails to improve outcome in an antibiotic treated canine model of human septic shock. Transfusion 1993; 33:243-248
52. Petros A, Bennett D, Vallance P Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991; 338:1557-1558
53. G-amino-L-arginine, an inhibitor of nitric oxide synthase, increases lethality in canine endotoxic shock. Clin Res 1991; 39:321A-321A abstract.